Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity.

Cancer Cell
Andrew ChowTaha Merghoub

Abstract

Immune checkpoint blockade (ICB) has been a remarkable clinical advance for cancer; however, the majority of patients do not respond to ICB therapy. We show that metastatic disease in the pleural and peritoneal cavities is associated with poor clinical outcomes after ICB therapy. Cavity-resident macrophages express high levels of Tim-4, a receptor for phosphatidylserine (PS), and this is associated with reduced numbers of CD8+ T cells with tumor-reactive features in pleural effusions and peritoneal ascites from patients with cancer. We mechanistically demonstrate that viable and cytotoxic anti-tumor CD8+ T cells upregulate PS and this renders them susceptible to sequestration away from tumor targets and proliferation suppression by Tim-4+ macrophages. Tim-4 blockade abrogates this sequestration and proliferation suppression and enhances anti-tumor efficacy in models of anti-PD-1 therapy and adoptive T cell therapy in mice. Thus, Tim-4+ cavity-resident macrophages limit the efficacy of immunotherapies in these microenvironments.

References

Oct 26, 2007·Nature·Masanori MiyanishiShigekazu Nagata
Sep 19, 2008·Nature Immunology·Tracy S P HengUNKNOWN Immunological Genome Project Consortium
Feb 6, 2010·Proceedings of the National Academy of Sciences of the United States of America·Eliver Eid Bou GhosnLeonore A Herzenberg
Apr 7, 2010·Proceedings of the National Academy of Sciences of the United States of America·Roselynn Rodriguez-ManzanetVijay K Kuchroo
Apr 28, 2010·Proceedings of the National Academy of Sciences of the United States of America·Kit WongWenjun Ouyang
Nov 3, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Lee A AlbackerRosemarie H DeKruyff
Jun 23, 2012·International Immunology·Masanori MiyanishiShigekazu Nagata
Mar 29, 2014·The Journal of Clinical Investigation·Alena GrosSteven A Rosenberg
Feb 24, 2015·Respirology : Official Journal of the Asian Pacific Society of Respirology·Jose M PorcelAntonieta Salud
Jan 28, 2016·Nature Communications·Charlotte L ScottMartin Guilliams
Jun 25, 2016·Nature Reviews. Cancer·Camilla EngblomMikael J Pittet
Nov 12, 2016·Cancer Gene Therapy·W F MoranoW B Bowne
Feb 6, 2018·Cellular Immunology·Calum C Bain, Stephen J Jenkins
Apr 11, 2018·Proceedings of the National Academy of Sciences of the United States of America·Elisa PeranzoniEmmanuel Donnadieu
Jul 15, 2018·Nature Communications·Thomas DuhenAndrew D Weinberg
Sep 12, 2018·The Journal of Experimental Medicine·Pierre-Louis LoyherAlexandre Boissonnas
Feb 6, 2019·Nature Reviews. Immunology·David G DeNardo, Brian Ruffell
Apr 20, 2019·Journal for Immunotherapy of Cancer·Albert D DonnenbergVera S Donnenberg
May 16, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K HastingsK Politi
Jun 11, 2019·Cell·Tim StuartRahul Satija
Nov 2, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Juan C OsorioMatthew D Hellmann
Nov 20, 2019·Nature Methods·Ilya KorsunskySoumya Raychaudhuri
Nov 30, 2019·Nature Communications·Jesse A Rudd-SchmidtIlia Voskoboinik
Jan 18, 2020·The Journal of Experimental Medicine·Anders EtzerodtToby Lawrence
Apr 5, 2020·Nature Communications·María Casanova-AcebesMercedes Ricote
Jun 20, 2020·Immunity·Camille BlériotFlorent Ginhoux
Oct 4, 2020·Science Immunology·James C LeeJeffrey A Bluestone

❮ Previous
Next ❯

Citations

Jul 15, 2021·Cancer Cell·Paulo C Rodriguez, Brian Ruffell
Oct 7, 2021·Journal of Leukocyte Biology·Jasmine J M ChuahNicole K Campbell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

CZI Human Cell Atlas Seed Network

The aim of the Human Cell Atlas (HCA) is to build reference maps of all human cells in order to enhance our understanding of health and disease. The Seed Networks for the HCA project aims to bring together collaborators with different areas of expertise in order to facilitate the development of the HCA. Find the latest research from members of the HCA Seed Networks here.